macular degeneration

Per aspera ad astra – Through hardships to the starsAccording to the latest data by the World Health Organization, there are approximately 36 million blind people in the world, and the numbers keep growing due to increasing population sizes in developing countries and rising life expectancies in developed nations.
Electroretinography: Out of the laboratory and into the clinicOCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Identifying common macular conditions with OCTEffectively manage patients through diagnosis and interpretation
The case of the disappearing drusen
The case of the disappearing drusenAt her periodic eye examination, a female patient in her early 70s was discovered to have low-risk macular degeneration in each eye. Further evaluation revealed that her visual acuity (VA) was correctable to 20/25 in each eye.
Community monitoring of nAMD as effective as hospital monitoringCommunity monitoring of neovascular age-related macular degeneration (nAMD) can be just as effective as hospital-based monitoring, researchers say.
The AAO's preferred practice patterns for AMDHigh-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.
FDA's Avastin rules may not be necessaryWhile FDA is proposing that bevacizumab (Avastin) for macular degeneration be used within 5 days of re-packaging to avoid development of endophthalmitis in patients, that precaution may not be necessary, according to a new study.
Primary care optometry: addressing the posterior segmentDuring the American Academy of Optometry's Academy 2014, experts elucidated with promising directions for retinal and other posterior eye problems.
Verteporfin does not improve efficacy of ranibizumab for AMD (VIDEO)William Fredette, MD, discusse the results of two trials published in Opthalmology, which indicate that the combination of Verteporfin Photodynamic Therapy plus ranibizumab injections is no better than ranibizumab alone for treating subfoveal choroidal neovascularization secondary to AMD. Video provided by The Doctor's Channel.